Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Medivation: No to Sanofi’s Renewed Press to Take $9.3B Offer

By LINDA A. JOHNSON, AP Business Writer | May 6, 2016

Medivation again rejected Sanofi’s bid to acquire the biologic drugmaker for $9.3 billion, saying Thursday that it “substantially undervalues” Medivation and its prospects.

The swift response came hours after Paris-based Sanofi, France’s biggest drugmaker, threatened Medivation’s board members with possible removal if they won’t discuss a deal.

Sanofi SA released a letter it sent to the board of Medivation, which about a month ago became a hot acquisition target for large multinational drugmakers looking for ways to boost their medicine portfolios and future sales.

The letter stated that the acquisition is a “priority for Sanofi.” It said Sanofi might raise its offer price if Medivation will discuss the deal and can show “additional value,” adding Sanofi will attempt to replace Medivation’s board members if they don’t negotiate. Sanofi added that it’s talked with Medivation’s top shareholders and believes “there is overwhelming support by your shareholders for a transaction.”

On April 28 Sanofi offered $9.3 billion in cash, or $52.50 per share, for the San Francisco drugmaker, well above its $37 range before deal rumors began. Medivation’s board promptly rejected the offer as too low.

On Thursday, Medivation said in a brief statement that “Sanofi’s letter simply restates an inadequate proposal” that undervalues the company, “its leading oncology franchise, and innovative late-stage pipeline.” The statement said the board “believes the execution of Medivation’s business plan will deliver value to its stockholders that is far superior to Sanofi’s proposal.”

Medivation is a specialty drugmaker, focused on developing medicines for cancer and serious diseases with few treatment options. It has only one approved product, Xtandi for advanced prostate cancer that doesn’t respond to hormone-based medicines. Its pipeline includes enzalutamide, in mid- and late-stage patient testing for prostate, liver and breast cancer, plus talazoparib for breast cancer and pidilizumab, which is in mid-stage testing against the blood cancer B-cell lymphoma.

Last year, Medivation posted revenue of $943.3 billion, about half of it from Xtandi and the rest from payments from various collaborators.

The company released its first-quarter financial results after the market closed Thursday. Medivation swung to a profit of $4.82 million, or 3 cents per share, for the first three months of the year. Adjusted earnings per share improved to 11 cents, while revenue rose 41 percent to $182.5 million. The stock closed regular trading up 16 cents at $59.22 and then added 18 cents in after-hours trading. Sanofi’s U.S. shares closed regular trading up 32 cents at $39.07.

Meanwhile, other major drugmakers with cancer medicine franchises are reportedly considering bidding for Medivation, including Pfizer Inc., Amgen Inc., AstraZeneca PLC and Novartis AG.

Sanofi’s letter to Medivation is signed by Chief Executive Olivier Brandicourt, a trained physician who arrived at Sanofi in April 2015 from Bayer, after spending 13 years in executive positions at New York-based Pfizer. Over that span, Pfizer grew dramatically through three mega-acquisitions. But in 2014 and again this year, Pfizer failed in attempted mergers with Europe-based drugmakers — AstraZeneca PLC and Allergan PLC, respectively — that would have allowed Pfizer to move its headquarters on paper from the U.S. to a lower-tax country.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE